Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121685 | 0.94 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ASSTR5KCNH2 | |
| SCHEMBL16056243 | 0.88 | ALDH1A1 (0.44) | ALDH1A1FDPSMEN1HPGDKMT2A | |
| SCHEMBL16055771 | 0.86 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ATUBB1SSTR5 | |
| SCHEMBL16056410 | 0.86 | KDM4E (0.46) | ALDH1A1MEN1POLBHPGDKMT2A | |
| SCHEMBL16055166 | 0.86 | ALDH1A1 (0.46) | ALDH1A1MEN1HPGDKMT2ASSTR5 | |
| SCHEMBL16616064 | 0.85 | ALDH1A1 (0.43) | ALDH1A1SSTR5KCNH2KDM4E | |
| SCHEMBL18832565 | 0.85 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ASSTR5KCNH2 | |
| SCHEMBL16056088 | 0.85 | ALDH1A1 (0.48) | ALDH1A1MEN1HPGDKMT2ASSTR5 | |
| SCHEMBL17535630 | 0.84 | ALDH1A1 (0.39) | ALDH1A1FDPSMEN1KMT2ASSTR5 | |
| SCHEMBL2954865 | 0.83 | KDM4E (0.48) | ALDH1A1HPGDSSTR5KCNH2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970331-B1 | SPIRO AZETIDINE ISOXAZOLE DERIVATIVES AND THEIR USE AS SSTR5 ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-9605000-B2 | Spiro azetidine isoxazole derivatives and their use as SSTR antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-28 | — | — | US | disclosed |
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060273-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR1, SSTR2 | ALDH1A1 2449/4885FDPS 3507/4885MEN1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.